Polar Asset Management Partners’s Vaxcyte PCVX Stock Holding History

Polar Asset Management Partners’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,004	Closed	-$378K	–	689
2025 Q1	$378K	Buy	+10,004	New	+$800K	0.01%	345
2024 Q4	–	Sell	-54,000	Closed	-$6.17M	–	765
2024 Q3	$6.17M	Sell	54,000 -44,200	-45%	-$3.98M	0.13%	162
2024 Q2	$7.42M	Sell	98,200 -6,279	-6%	-$427K	0.15%	140
2024 Q1	$7.14M	Sell	104,479 -109,800	-51%	-$7.6M	0.12%	142
2023 Q4	$13.5M	Sell	214,279 -111,300	-34%	-$5.78M	0.23%	85
2023 Q3	$16.6M	Hold	325,579	–	–	0.37%	71
2023 Q2	$16.3M	Sell	325,579 -87,721	-21%	-$4.16M	0.29%	80
2023 Q1	$15.5M	Sell	413,300 -142,600	-26%	-$6.05M	0.24%	112
2022 Q4	$26.7M	Buy	555,900 +200,200	+56%	+$7.86M	0.33%	41
2022 Q3	$8.54M	Hold	355,700	–	–	0.1%	312
2022 Q2	$7.74M	Buy	+355,700	New	+$8.23M	0.09%	338

Other funds holding PCVX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Polar Asset Management Partners's PCVX Position: Q2 2025 in Review

Polar Asset Management Partners sold out of Vaxcyte (PCVX) in Q2 2025, closing a stake of 10,004 shares — an estimated $378K sold.

Polar Asset Management Partners first reported a position in PCVX in Q2 2022 and held it in 11 quarters. The position peaked at $26.7M in Q4 2022. 294 funds tracked by Wall St. Rank hold PCVX as of Q2 2025.

Polar Asset Management Partners reported no remaining Vaxcyte position as of Q2 2025 after selling out during the quarter.
Polar Asset Management Partners sold 10,004 Vaxcyte shares in Q2 2025, an estimated $378K.
Polar Asset Management Partners first reported a position in Vaxcyte in Q2 2022 and held it in 11 quarters.
Polar Asset Management Partners's Vaxcyte position peaked at $26.7M in Q4 2022.
294 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2025.

Based on Polar Asset Management Partners's 13F filing for Q2 2025, filed 14 Aug 2025.